Company Overview

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a U.S.-based biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company operates within the ophthalmology and biotechnology industries, with an emphasis on sustained-delivery drug technologies for chronic eye conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and non-proliferative diabetic retinopathy (NPDR). EyePoint’s primary value proposition centers on reducing treatment burden for patients and physicians through long-acting intraocular therapies.

The company’s core pipeline is led by DURAVYU (formerly EYP-1901), an investigational sustained-delivery intravitreal treatment that uses bioerodible Durasert technology to deliver vorolanib, a tyrosine kinase inhibitor. Historically, EyePoint also generated revenue through commercial ophthalmic products including YUTIQ and DEXYCU, though the company has increasingly shifted toward a clinical-stage biotechnology model focused on retinal therapeutics. EyePoint traces its origins to pSivida Corp., an ocular drug-delivery company founded in Australia in 2000; following corporate restructuring and strategic refocusing, the company adopted the EyePoint Pharmaceuticals name in 2018.

Business Operations

EyePoint’s operations are centered on research, development, and commercialization activities in ophthalmology. Its principal operating focus is the advancement of sustained-delivery retinal disease therapies using its proprietary Durasert drug-delivery platform. The company’s revenue historically came from product sales, license agreements, and collaborations associated with products such as YUTIQ and DEXYCU, although recent financial filings indicate that research and development activities tied to DURAVYU and broader retinal programs now represent the company’s primary strategic priority.

The company operates primarily in the United States but has historically maintained international licensing relationships and supply-chain partnerships connected to ophthalmic products and technology development. EyePoint controls intellectual property related to sustained intraocular drug-delivery systems and maintains manufacturing and clinical development capabilities through internal operations and third-party partnerships. The company has also collaborated with contract research organizations, manufacturing providers, and retinal specialists to support clinical trials and regulatory development programs.

Strategic Position & Investments

EyePoint’s strategic direction is focused on becoming a retinal disease therapeutics company built around long-acting drug delivery. The company has prioritized the development of DURAVYU for wet AMD and diabetic retinal diseases, positioning the therapy as a potential alternative to frequent anti-VEGF injections. This strategy reflects broader industry demand for therapies that reduce injection frequency while maintaining efficacy in chronic retinal conditions.

The company has invested significantly in clinical development programs, including Phase 2 and Phase 3 planning activities associated with DURAVYU. EyePoint has also emphasized expansion of its retinal pipeline through additional sustained-delivery formulations and platform applications. Historically, the company divested or deprioritized certain commercial operations to concentrate capital on late-stage retinal development initiatives. Public filings and investor materials indicate that EyePoint views sustained ocular delivery technology as its primary competitive differentiator within the ophthalmology market.

Geographic Footprint

EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts, and its principal operations are concentrated in the United States. The company’s clinical development activities involve collaboration with retinal specialists, investigators, and clinical trial sites across North America. Commercial and regulatory engagement has historically centered on the U.S. ophthalmology market, which remains its largest operational focus.

Although EyePoint does not maintain the same multinational commercial footprint as larger pharmaceutical companies, it has participated in international licensing arrangements and maintains intellectual property protections across multiple jurisdictions. Its technologies and clinical programs have relevance in major ophthalmology markets including North America, Europe, and parts of the Asia-Pacific region, particularly where retinal disease prevalence and anti-VEGF treatment demand are growing.

Leadership & Governance

EyePoint’s leadership team is composed of executives with backgrounds in biotechnology, ophthalmology, pharmaceutical commercialization, and capital markets. The company’s governance structure follows standard U.S. public-company practices, with oversight provided by a board of directors and executive leadership team. Corporate strategy has increasingly emphasized disciplined capital allocation, retinal disease specialization, and clinical execution in late-stage ophthalmology programs.

Key executives include:

• Jay S. Duker – President and Chief Executive Officer
• George Elston – Chief Financial Officer
• David Guyer – Chair of the Board
• Robert L. Avery – Board Member
• Nancy Lurker – Board Member

Leadership communications in public filings and investor presentations consistently emphasize sustained drug delivery, reduction of treatment burden in retinal disease, and advancement of long-duration ophthalmic therapies as central components of the company’s long-term strategy.